{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Arunachalam_et_al.__2021_",
  "verification_stats": {
    "total_extracted": 1,
    "verified": 0,
    "rejected": 1,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "A plant derived recombinant quad rival ent VLP (QVLP) at 30 \u00b5g dose per strain was found to be non inferior in terms of vaccine efficacy against respiratory illness and influenza like illness to a quad rival ent in activated influenza vaccine (QIV; Fluarix Quad rival ent, Glaxo smith kline) given at 15 \u00b5g dose strain in adults aged 18 to 64 years 37.",
      "reason": "does not support claim",
      "original_explanation": "This quote describes a clinical trial in which a plant-derived quadrivalent VLP vaccine was compared to Fluarix Quadrivalent (a standard-dose quadrivalent vaccine), supporting the claim that Flublok (quadrivalent) was evaluated against Fluarix (quadrivalent standard-dose vaccine)."
    }
  ],
  "model_used": "gpt-4.1"
}